Advertisement

PharmacoEconomics & Outcomes News

, Volume 844, Issue 1, pp 15–15 | Cite as

Docetaxel cost-saving alternative to abiraterone in prostate cancer

Clinical study
  • 2 Downloads

Reference

  1. Hu X, et al. Abiraterone acetate and docetaxel with androgen deprivation therapy in high-volume metastatic hormone-sensitive prostate cancer in China: an indirect treatment comparison and cost analysis. Cost Effectiveness and Resource Allocation : 13 Dec 2019. Available from: URL: https://doi.org/10.1186/s12962-019-0193-4

Copyright information

© Springer International Publishing AG 2020

Personalised recommendations